{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:36:39Z","timestamp":1788572199603,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7192218"],"award-info":[{"award-number":["7192218"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00280-023-04581-0","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:02:14Z","timestamp":1692957734000},"page":"399-410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation"],"prefix":"10.1007","volume":"92","author":[{"given":"Shiyu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-1374","authenticated-orcid":false,"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,25]]},"reference":[{"issue":"5","key":"4581_CR1","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8(5):935\u2013942","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4581_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clinthera.2019.10.009","volume":"41","author":"M Garc\u00eda-Ferrer","year":"2019","unstructured":"Garc\u00eda-Ferrer M, Wojnicz A, Mej\u00eda G, Koller D, Abad-Santos F (2019) Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: a systematic review and meta-analysis. Clin Ther 41(12):22","journal-title":"Clin Ther"},{"issue":"4","key":"4581_CR3","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984","journal-title":"Leukemia"},{"issue":"10","key":"4581_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK et al (2020) Chronic myeloid leukemia, version 22021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18(10):1385\u20131415","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"4581_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894","journal-title":"Clin Pharmacokinet"},{"key":"4581_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","volume":"157","author":"WA Clarke","year":"2021","unstructured":"Clarke WA, Chatelut E, Fotoohi AK et al (2021) Therapeutic drug monitoring in oncology: International association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy. Euro J Cancer. 157:428\u2013440","journal-title":"Euro J Cancer."},{"issue":"8","key":"4581_CR7","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496\u20133499","journal-title":"Blood"},{"issue":"8","key":"4581_CR8","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022\u20134028","journal-title":"Blood"},{"issue":"4","key":"4581_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/hon.2005","volume":"30","author":"M Koren-Michowitz","year":"2012","unstructured":"Koren-Michowitz M, Volchek Y, Naparstek E et al (2012) Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 30(4):200\u2013205","journal-title":"Hematol Oncol"},{"issue":"14","key":"4581_CR10","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon F-X et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381\u20132388","journal-title":"J Clin Oncol"},{"issue":"5","key":"4581_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3324\/haematol.2011.045666","volume":"97","author":"F Guilhot","year":"2012","unstructured":"Guilhot F, Hughes TP, Cortes J et al (2012) Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica 97(5):731\u2013738","journal-title":"Haematologica"},{"issue":"2","key":"4581_CR12","doi-asserted-by":"publisher","first-page":"E363","DOI":"10.1208\/aapsj070237","volume":"7","author":"PL Bonate","year":"2005","unstructured":"Bonate PL (2005) Recommended reading in population pharmacokinetic pharmacodynamics. Aaps j 7(2):E363\u2013E373","journal-title":"Aaps j"},{"key":"4581_CR13","unstructured":"FDA. FDA Guidance for Industry on \"Population Pharmacokinetics\". 1999;"},{"issue":"4","key":"4581_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/bcp.15122","volume":"88","author":"\u00c1 Corral Alaejos","year":"2021","unstructured":"Corral Alaejos \u00c1, Zarzuelo Casta\u00f1eda A, Jim\u00e9nez Cabrera S, S\u00e1nchez-Guijo F, Otero MJ, P\u00e9rez-Blanco JS (2021) External Evaluation of Population Pharmacokinetic Models of Imatinib in Adults Diagnosed with Chronic Myeloid Leukaemia. Br J Clin Pharmacol 88(4):1913\u20131924","journal-title":"Br J Clin Pharmacol"},{"key":"4581_CR15","unstructured":"(NCCN) NCCN. NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia (Version 3.2022). available at http:\/\/www.nccn.org\/patients. Accessed 27 Jan 2022;"},{"issue":"9","key":"4581_CR16","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"21","key":"4581_CR17","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14(21):7102\u20137109","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4581_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2217\/pgs-2018-0139","volume":"20","author":"Q Wang","year":"2019","unstructured":"Wang Q, Jiang ZP, Yu EQ et al (2019) Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia. Pharmacogenomics 20(4):251\u2013260","journal-title":"Pharmacogenomics"},{"issue":"20","key":"4581_CR19","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","volume":"18","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, Fransson MN, Reyners AK et al (2012) A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 18(20):5780\u20135787","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4581_CR20","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102(5):765\u2013776","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"4581_CR21","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","volume":"50","author":"N Widmer","year":"2014","unstructured":"Widmer N, Bardin C, Chatelut E et al (2014) Review of therapeutic drug monitoring of anticancer drugs part two\u2013targeted therapies. Eur J Cancer 50(12):2020\u20132036","journal-title":"Eur J Cancer"},{"issue":"4","key":"4581_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","volume":"53","author":"H Yu","year":"2014","unstructured":"Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 53(4):305\u2013325","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4581_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","volume":"62","author":"N Widmer","year":"2006","unstructured":"Widmer N, Decosterd LA, Csajka C et al (2006) Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 62(1):97\u2013112","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"4581_CR24","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/jcph.953","volume":"57","author":"BA Adeagbo","year":"2017","unstructured":"Adeagbo BA, Olugbade TA, Durosinmi MA, Bolarinwa RA, Ogungbenro K, Bolaji OO (2017) Population Pharmacokinetics of imatinib in nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance. J Clin Pharmacol 57(12):1554\u20131563","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"4581_CR25","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00228-022-03345-8","volume":"78","author":"B Shriyan","year":"2022","unstructured":"Shriyan B, Mehta P, Patil A et al (2022) Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia. Eur J Clin Pharmacol 78(8):1321\u20131330","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"4581_CR26","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/tpj.2014.7","volume":"14","author":"A Di Paolo","year":"2014","unstructured":"Di Paolo A, Polillo M, Capecchi M et al (2014) The c480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 14(4):328\u2013335","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"4581_CR27","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s13318-015-0292-3","volume":"41","author":"AA Golabchifar","year":"2016","unstructured":"Golabchifar AA, Rezaee S, Dinan NM, Kebriaeezadeh A, Rouini MR (2016) Population pharmacokinetic analysis of the oral absorption process and explaining intra-subject variability in plasma exposures of imatinib in healthy volunteers. Eur J Drug Metab Pharmacokinet 41(5):527\u2013539","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"4581_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/bcp.12584","volume":"80","author":"D Renard","year":"2015","unstructured":"Renard D, Bouillon T, Zhou P, Flesch G, Quinn D (2015) Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension. Br J Clin Pharmacol 80(1):75\u201385","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4581_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-2125.2005.02372.x","volume":"60","author":"H Schmidli","year":"2005","unstructured":"Schmidli H, Peng B, Riviere GJ et al (2005) Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 60(1):35\u201344","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4581_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","volume":"55","author":"I Judson","year":"2005","unstructured":"Judson I, Ma P, Peng B et al (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time EORTC soft tissue and bone sarcoma group. Cancer Chemother Pharmacol 55(4):379\u2013386","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4581_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1365-2125.2004.02117.x","volume":"58","author":"O Kretz","year":"2004","unstructured":"Kretz O, Weiss HM, Schumacher MM, Gross G (2004) In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 58(2):212\u2013216","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"4581_CR32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1211\/jpp.58.8.0006","volume":"58","author":"H Prenen","year":"2006","unstructured":"Prenen H, Guetens G, De Boeck G, Highley M, van Oosterom AT, de Bruijn EA (2006) Everolimus alters imatinib blood partition in favour of the erythrocyte. J Pharm Pharmacol 58(8):1063\u20131066","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"4581_CR33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.2007.13.3819","volume":"26","author":"J Gibbons","year":"2008","unstructured":"Gibbons J, Egorin MJ, Ramanathan RK et al (2008) Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26(4):570\u2013576","journal-title":"J Clin Oncol"},{"issue":"20 Pt 1","key":"4581_CR34","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","volume":"12","author":"C Delbaldo","year":"2006","unstructured":"Delbaldo C, Chatelut E, R\u00e9 M et al (2006) Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Can Res 12(20 Pt 1):6073\u20136078","journal-title":"Clin Can Res"},{"issue":"19","key":"4581_CR35","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors. J Clin Oncol 27(19):3141\u20133147","journal-title":"J Clin Oncol"},{"issue":"3","key":"4581_CR36","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ki.2013.399","volume":"85","author":"CK Yeung","year":"2014","unstructured":"Yeung CK, Shen DD, Thummel KE, Himmelfarb J (2014) Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 85(3):522\u2013528","journal-title":"Kidney Int"},{"issue":"6","key":"4581_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40262-014-0146-1","volume":"53","author":"L Lalande","year":"2014","unstructured":"Lalande L, Charpiat B, Leboucher G, Tod M (2014) Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet 53(6):521\u2013532","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4581_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cpt.757","volume":"102","author":"JO Miners","year":"2017","unstructured":"Miners JO, Yang X, Knights KM, Zhang L (2017) The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance. Clin Pharmacol Ther 102(3):436\u2013449","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4581_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","volume":"63","author":"D Menon-Andersen","year":"2009","unstructured":"Menon-Andersen D, Mondick JT, Jayaraman B et al (2009) Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 63(2):229\u2013238","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"4581_CR40","first-page":"26","volume":"1","author":"M Ansari","year":"2016","unstructured":"Ansari M, Kalantary-Khandani B, Pardakhty A, Safavi M, Mosavi N, Mohajeri E (2016) Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population. Gulf J Oncolog 1(22):26\u201336","journal-title":"Gulf J Oncolog"},{"issue":"7","key":"4581_CR41","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","volume":"38","author":"V Gotta","year":"2014","unstructured":"Gotta V, Bouchet S, Widmer N et al (2014) Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 38(7):764\u2013772","journal-title":"Leuk Res"},{"issue":"4","key":"4581_CR42","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.3390\/ijms24043303","volume":"24","author":"C Dalle Fratte","year":"2023","unstructured":"Dalle Fratte C, Polesel J, Gagno S et al (2023) Impact of ABCG2 and ABCB1 polymorphisms on imatinib plasmatic exposure: an original work and meta-analysis. Int J Mol Sci 24(4):3303","journal-title":"Int J Mol Sci"},{"key":"4581_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2551-x","author":"SA Smith","year":"2019","unstructured":"Smith SA, Waters NJ (2019) Pharmacokinetic and Pharmacodynamic considerations for drugs binding to alpha-1-Acid glycoprotein. Pharma Res. https:\/\/doi.org\/10.1007\/s11095-018-2551-x","journal-title":"Pharma Res."}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04581-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:05:53Z","timestamp":1694750753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04581-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["4581"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04581-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted following the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the Peking University People\u2019s Hospital (2022PHB095-001).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}